Have you heard about induced pluripotent stem cells (iPS cells), but don’t know exactly what they are and what they can do? If so, read on to learn the answers to frequently asked questions (FAQs) about iPS cells.
In this article:
Your Global Leader in Stem Cell Market Research

Have you heard about induced pluripotent stem cells (iPS cells), but don’t know exactly what they are and what they can do? If so, read on to learn the answers to frequently asked questions (FAQs) about iPS cells.
In this article:

HOUSTON, July 29, 2026 — Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for hNPC01, an allogeneic induced pluripotent stem cell (iPSC)-derived forebrain neural progenitor cell therapy, for the treatment of chronic motor dysfunction due to Hemorrhagic Stroke (ICH) and Traumatic Brain Injury (TBI). [Read more…]

Lab-grown meat, now more commonly referred to as cultivated meat, cell-cultured meat, or cellular agriculture, has evolved from a speculative biotechnology concept into an emerging commercial sector attracting investors, biotechnology companies, food industry leaders, and researchers worldwide.
Produced by expanding animal cells from species such as cattle, pigs, chicken, fish, and other livestock within controlled bioreactor environments, cultivated meat has the potential to reshape portions of the global protein market. Rather than raising and slaughtering animals, cultivated meat companies use cellular agriculture techniques to produce animal-derived tissues directly from cells. [Read more…]

CHICAGO & MILPITAS, Calif. — Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advance stem cell research and therapeutic application discovery and development. [Read more…]

MILPITAS, Calif. and FREDERICK, Md., July 8, 2026 — Applied StemCell, Inc., a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions. The collaboration combines Applied StemCell’s GMP-compatible iPSC technology with RoosterBio’s engineered media systems and scalable manufacturing expertise to provide advanced therapy developers with a unique bioprocess solution supporting research through clinical manufacturing. [Read more…]